Introduction
Myeloablative Allo-SCT can cure hematological malignancies that are not curable with conventional therapies. 1 Its efficacy is dependent on the anti-leukemic activity of both the conditioning regimen and the GVL effect of the donor lymphocytes. However, the wide-spread application of Allo-SCT has been limited by the toxicities associated with the conditioning regimens. 2 One avenue that has been explored to broaden the applicability of Allo-SCT is to reduce the intensity of the conditioning regimen to minimize toxicity and to rely more on the GVL effects. The GVL in AML and myelodysplastic syndrome (MDS) is evidenced by the efficacy of donor lymphocyte infusions in treating post-Allo-SCT relapses and by the observation that most patients who expire after transplant die of treatment-related mortality rather than disease relapse. 3, 4 This is in contrast to diseases such as acute lymphoblastic leukemia, in which relapse rates after Allo-SCT remain relatively high. 5 As a result, there has been a proliferation of reduced-intensity conditioning regimens investigated in the past decade, particularly in older patients and those whose comorbidites preclude them from receiving a fully myeloablative regimen. 6, 7 Typically these regimens tradeoff lower toxicity for higher rates of relapse because of a decrease in the anti-leukemic activity of the conditioning regimen. 8 The combination of fludarabine (Flu) and half the myeloablative dose of BU (Flu/BU), with or without anti-thymocyte globulin (ATG), is one of the most commonly used reduced-intensity regimens. 9, 10 At the dose at which Flu is used in the Flu/BU regimen, it primarily acts as an immunosuppressant and has little antileukemic activity. Though BU provides some anti-leukemic activity, arguably, the efficacy of the regimen is highly dependent mainly on the GVL effects of the graft. Clofarabine is a novel nucleoside analog with a stronger anti-leukemia effect than Flu. 11 It has shown activity in myeloid malignancies both in the salvage and in the up-front settings. [12] [13] [14] Furthermore, it has both preclinical and clinical evidence suggesting synergism with cytarabine. 15, 16 On the basis of the relative merits of clofarabine over Flu and with the evidence of its increased anti-leukemic activity when combined with cytarabine, we designed a novel allogeneic transplant regimen for AML in remission and MDS with clofarabine, cytarabine and ATG. We felt that this regimen would afford greater anti-leukemic activity than the standard Flu/BU regimen while still achieving engraftment.
Methods

Patients
The protocol was approved by the Institutional Review Board at the Washington University School of Medicine. All patients provided written informed consent. Patients were eligible for protocol therapy if they had MDS as defined by the WHO (World Health Organization), chronic myelomonocytic leukemia as defined by the FAB classification, or AML, excluding acute promyelocytic leukemia. Patients with AML had to be in a morphologic CR by BM examination, but those with MDS and chronic myelomonocytic leukemia could be in any phase of the disease. Patients had to be at least 18 years of age without a predefined upper age limit, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and have a suitable donor identified.
Other inclusion and exclusion criteria included a diffusing capacity of the lung for carbon monoxide (DLCO) 440% with no symptomatic pulmonary disease, left ventricular ejection fraction of 430% by multigated acquistion (MUGA) scan, bilirubin p2 Â the upper limit of normal (ULN), aspartate aminotransferase (AST) p3 Â ULN and a serum creatinine p1.0 mg/100 ml; if serum creatinine 41.0 mg/100 ml, then the estimated glomerular filtration rate must be 450 ml/min per 1.73 m /day i.v. on days þ 1, þ 3 and þ 6; matched unrelated donors also received a dose on day þ 11). Herpes simplex, fungal and pneumocystic carinii pnenmonia (PCP) prophylaxis were administered. Serum CMV PCRs were monitored weekly.
Statisitical analysis
This study was designed as an open-label phase II study to evaluate the conditioning regimen's 6-month treatmentrelated mortality. Planned secondary end points included rates of both acute and chronic GVHD, disease-specific response rates for MDS, median time to progression, disease-free survival, OS and engraftment as measured by percentage donor chimerism by variable number tandem repeats (VNTR) at day þ 30, þ 60 and þ 90. Analysis was conducted using GraphPad Prism version 5.0. The study was planned to accrue 20 patients. Predefined early stopping rules for the trial were defined such that if three deaths occurred in the first 11 patients then the trial was unlikely to achieve a low treatment-related mortality.
Results
Patient characteristics
Seven of the planned 20 patients were enrolled and completed the conditioning regimen. The median age was 54 years (range ¼ 24-68) ( Table 1) . Three of seven patients had MDS (WHO classifications RAEB, RAEB-2 and RCMD-RS; all three had received hypomethylating agents and achieved stable disease before transplant) and four patients had AML (FAB classifications M1, M0, M5b and M1; two were in CR1 after standard induction and up to 2 cycles of consolidation, one had received 17 cycles of decitibine, one was in CR3 and had received a prior allogeneic transplantation).
Stem cell product
The source of stem cells was matched unrelated donors in four patients and matched sibling donors in three patients. cells/kg).
Engraftment and chimerism
The median duration of neutropenia (ANCo500) was 14 days (range ¼ 12-16), with two patients expiring before ANC recovery. The median duration of thrombocytopenia (Pltso50 000) was 22 days (range ¼ 10-33), with three patients expiring before Plt recovery. All of the patients surviving to day þ 40-60 achieved some degree of donor engraftment, though it was complete only in one patient (others: 60% (peripheral blood), 70% (BM) and 75% (BM)).
Efficacy and survival
Enrollment to the trial was halted after three of the first seven patients (one with MDS and two with AML) expired on days þ 15, þ 26 and þ 32. This fulfilled the predefined stopping rule as it was unlikely that we would achieve our primary end point of a 6 month treatment-related mortality of 10%. Of the surviving four patients, three relapsed with a median TTP of 152 days (range ¼ 98-154 days). One patient, with AML, remains in remission on day þ 120 but with incomplete donor chimerism (day þ 93-73% myeloid and 80% lymphoid). The cause of death was sepsis in two patients and veno-occlusive disease (VOD) in one patient. The patient who died of VOD had no history of liver disease and had not received gemtuzumab before, but had been on prolonged azole therapy for an invasive fungal infection.
Toxicity
Forty-three per cent (3/7) of patients had grade 3/4 anemia; 71% (5/7) of patients had grade 3/4 neutropenia; and 57% (4/7) of patients had grade 3/4 thrombocytopenia. All patients experienced neutropenic fevers. Eighty-six per cent (6/7) of patients had a documented infection (one with CMV, one with Clostridium difficile colitis and four with bacteremia). Other toxicities included handfoot syndrome (all grade ¼ 57%, grade
No acute GVHD was observed.
Discussion
The role of clofarabine as an agent in conditioning regimens for allogeneic transplantation is just beginning to be explored. Initial reports have suggested success with clofarabine-based myeloablative conditioning regimens. Lang et al. 17 treated 10 children with refractory leukemias with a combination of clofarabine (50 mg/m 2 on days -8 to -5), thiotepa (10 mg/kg on day -4), melphalan (70 mg/m 2 on days -3 to -2) and OKT3 (0.1 mg/kg on day À8 to þ 14) or ATG (10 mg/kg) and achieved engraftment in all of them. They experienced no TRM and no grade 4 adverse events except for mucositis. The authors concluded that clofarabine had similar immunosuppressive effects to Flu and that it may replace Flu in conditioning regimens. Similarly, preliminary results of the combination of clofarabine and BU appear promising with all the evaluable patients achieving donor engraftment. Reported toxicities were manageable and there was no TRM. 18 This is the first paper to report on a reduced intensity regimen using clofarabine for allogeneic conditioning. We report an unacceptably high rate of poor donor chimerism. As our patients also had unacceptable toxicity, we do not believe that modifying the conditioning regimen by reducing or increasing the dose of clofarabine is likely to be a successful strategy. Total ATG doses of at least 6-8 mg/kg have been shown to decrease TRM without increasing the relapse rates. [19] [20] [21] Our regimen included a total dose of 6 mg/kg of ATG. Given that the rates of chimerism were lower than those seen with Flu plus BU with a similar dose of ATG, it is possible that clofarabine is less immunosuppressive than Flu. It is possible that a higher dose of ATG may have increased engraftment. 20 In addition, the half-life of ATG is 2-3 days. 22 It is possible that as our ATG was administered on days -4 to -2 the circulating levels of ATG would still be detectable when the graft was infused and this may have interfered with engraftment. We may have had better results if the ATG had been administered before the clofarabine and cytarabine rather than after.
The hand-foot syndrome with this regimen was pronounced (4/7 or 57% with grade 2). This is significantly higher than that reported with single agent clofarabine (13%) or clofarabine combined with low-dose cytarabine (13%). 23 However, this is nearly identical to the incidence of handfoot syndrome (45% grade 1 and 2; 5% grade 3) seen with the AML salvage regimen of clofarabine plus cytarabine (1 g/m 2 daily Â 5 days), which our regimen was based on. 15 Veno-occlusive disease has been described with other clofarabine-based regimens. 24 Of the fifteen cases reported earlier eight have occurred in the context of Allo-SCT, but others have occurred with single agent clofarabine. The pathogenesis of VOD in these 15 patients is complex and appears to be the confluence of multiple factors. The patient on our study with VOD had AML and had received standard induction with seven 7 þ 3 idarubicin and consolidation with two cycles of high-dose cytarabine. He had no prior history of hepatic disease, had never received gemtuzumab and had normal liver function tests and serum bilirubin at the beginning of conditioning. He had been on long-term azole therapy for an invasive fungal infection. His serum bilirubin began increasing on day þ 1 and increased dramatically until he expired. Another patient on the protocol experienced an elevated serum bilirubin, though he was extensively pretreated, including a prior Allo-SCT, and his liver function test elevation was in the context of multi-organ failure. The remainder of patients on the protocol experienced transient elevations of their liver function tests without further consequences, as had been reported earlier in the literature with clofarabine 15 ( Figure 1 ). This study should not necessarily be interpreted to show the lack of anti-leukemic activity of clofarabine plus cytarabine, but rather the lack, even with the addition of ATG, of substantially enough immunosuppression to allow for engraftment with this combination and provide an adequate GVL effect. The ongoing randomized CLAS-SIC I trial comparing clofarabine/cytarabine with intermediate-dose cytarabine (1 g/M 2 ) for AML salvage will help to clarify the anti-leukemic activity of clofarabine/ cytarabine. 25 In conclusion, this regimen of clofarabine/cytarabine/ ATG was not sufficiently immunosuppressive to ensure engraftment, and was associated with substantial morbidity and mortality. Other transplant regimens, both reduced intensity and myeloablative, incorporating clofarabine are currently being investigated. Transplant day Figure 1 Trends of liver function tests and bilirubin for the seven patients in the peri-transplant period.
